mmp -2触发，线粒体靶向PROTAC-PDT治疗乳腺癌和脑转移抑制

IF 14.7 1区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

Nature Communications Pub Date : 2024-11-29 DOI:10.1038/s41467-024-54854-2

Fan Tong, Yufan Wang, Yanyan Xu, Yang Zhou, Siqin He, Yufan Du, Wenqin Yang, Ting Lei, Yujun Song, Tao Gong, Huile Gao

{"title":"mmp -2触发，线粒体靶向PROTAC-PDT治疗乳腺癌和脑转移抑制","authors":"Fan Tong, Yufan Wang, Yanyan Xu, Yang Zhou, Siqin He, Yufan Du, Wenqin Yang, Ting Lei, Yujun Song, Tao Gong, Huile Gao","doi":"10.1038/s41467-024-54854-2","DOIUrl":null,"url":null,"abstract":"Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors. Herein, a transformable nanomedicine (dBET6@CFMPD) with mitochondrial targeting capacity is designed and constructed to combine PROTAC with photodynamic therapy (PDT). In this work, we demonstrate that dBET6@CFMPD exhibits great biodistribution and retention, and can induce potent antitumor response to suppress primary and metastatic tumors, becoming a nanomedicine with potential in cancer combination therapy.","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"272 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition\",\"authors\":\"Fan Tong, Yufan Wang, Yanyan Xu, Yang Zhou, Siqin He, Yufan Du, Wenqin Yang, Ting Lei, Yujun Song, Tao Gong, Huile Gao\",\"doi\":\"10.1038/s41467-024-54854-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors. Herein, a transformable nanomedicine (dBET6@CFMPD) with mitochondrial targeting capacity is designed and constructed to combine PROTAC with photodynamic therapy (PDT). In this work, we demonstrate that dBET6@CFMPD exhibits great biodistribution and retention, and can induce potent antitumor response to suppress primary and metastatic tumors, becoming a nanomedicine with potential in cancer combination therapy.\",\"PeriodicalId\":19066,\"journal\":{\"name\":\"Nature Communications\",\"volume\":\"272 1\",\"pages\":\"\"},\"PeriodicalIF\":14.7000,\"publicationDate\":\"2024-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Communications\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1038/s41467-024-54854-2\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-024-54854-2","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

Proteolytic targeting chimera （PROTAC）技术是一种具有抗肿瘤作用的蛋白阻断技术，具有潜在的优势。然而，由于其在肿瘤中的分布和蓄积不足，其作用受到限制。本文设计并构建了一种具有线粒体靶向能力的可变形纳米药物（dBET6@CFMPD），将PROTAC与光动力疗法（PDT）结合起来。在这项工作中，我们证明dBET6@CFMPD具有良好的生物分布和滞留性，可以诱导有效的抗肿瘤反应来抑制原发性和转移性肿瘤，成为一种具有癌症联合治疗潜力的纳米药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

查看原文本刊更多论文

MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors. Herein, a transformable nanomedicine (dBET6@CFMPD) with mitochondrial targeting capacity is designed and constructed to combine PROTAC with photodynamic therapy (PDT). In this work, we demonstrate that dBET6@CFMPD exhibits great biodistribution and retention, and can induce potent antitumor response to suppress primary and metastatic tumors, becoming a nanomedicine with potential in cancer combination therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Communications Biological Science Disciplines-

CiteScore

24.90

自引率

2.40%

发文量

6928

审稿时长

3.7 months

期刊介绍： Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.